Amicus Therapeutics Inc

Amicus Therapeutics’ insider liquidation after its BioMarin merger reveals a rare zero‑equity shift, raising questions on incentive alignment and future R&D success.

Amicus Therapeutics insider sale: CEO sells 22,500 shares at near 52‑week high, yet retains a million‑share stake—signals confidence, liquidity strategy, and future growth prospects for rare disease pipeline.

Amicus Therapeutics CEO buys shares at 50% discount, boosting confidence in Phase‑3 mepolizumab for PKU; insider move signals potential breakthrough approval and market shift.